Disclosures
Jiewei, Symbio
ONCOLOGY
Hideki Goto reports lecture fees earned from Kyowa Kirin. Satoshi Ito reports research funding from AbbVie, Amgen, Insight, Novartis, and Zenyaku-Kogyo. Masahiro Kizaki has nothing to declare. Masaki Yamaguchi has nothing to declare. Noriko Fukuhara reports research funding from AbbVie, Bayer, Celgene, Chordia Therapeutics, Chugai, Genmab, Incyte, Kyowa-Kirin, LOXO Oncology, and Takeda. Koji Kato reports research funding from AbbVie, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, and Takeda. Toko Saito has nothing to declare. Yasuhito Terui reports lecture fees earned from AbbVie, Celgene, Chugai, Eisai, Janssen, Ono, and Symbio and a certain contribution from Eisai. Sumiko Okubo reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Tomomi Soshin reports her and her husband’s employment with AbbVie and may hold stock options or other ownership in AbbVie. Jiewei Zeng reports employment with AbbVie and may hold stock options or other ownership in AbbVie. Hideyuki Honda reports employment with AbbVie and may hold stock options or other ownership in AbbVie. Mohamed Badawi reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Jeremy A. Ross reports employment with and research funding from AbbVie and may hold stock options or other ownership in AbbVie. Koji Izutsu reports advisory board and honoraria fees from AbbVie.